Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Centogene extends ROPAD study » 06:36
05/10/21
05/10
06:36
05/10/21
06:36
CNTG

Centogene

$9.76 /

+0.26 (+2.74%)

Centogene announced that…

Centogene announced that it has extended the Rostock International Parkinson's Disease Study. Having recently met the milestone of recruiting and performing genetic testing of 10,000 participants, the study now aims to recruit and test an additional 2,500 patients by the end of 2021 - helping to generate insights into one of Centogene's key prioritized diseases. Based on initial findings, the study will focus its efforts on 40 sites across 11 countries, including Brazil, Germany, Italy, Spain, and the U.S.

ShowHide Related Items >><<
CNTG Centogene
$9.76 /

+0.26 (+2.74%)

CNTG Centogene
$9.76 /

+0.26 (+2.74%)

11/05/20 Credit Suisse
Centogene initiated with an Outperform at Credit Suisse
CNTG Centogene
$9.76 /

+0.26 (+2.74%)

  • 10
    Jul
Over a week ago
Conference/Events
American College of Medical Genetics & Genomics » 04:55
04/16/21
04/16
04:55
04/16/21
04:55
APLT

Applied Therapeutics

$16.73 /

+0.16 (+0.97%)

, BNGO

Bionano Genomics

$6.12 /

-0.305 (-4.75%)

, CNTG

Centogene

$11.67 /

-0.73 (-5.89%)

, DGX

Quest Diagnostics

$129.23 /

+2.03 (+1.60%)

, FIXX

Homology Medicines

$7.03 /

-0.19 (-2.63%)

, FOLD

Amicus

$10.33 /

+0.345 (+3.46%)

, ILMN

Illumina

$401.83 /

+4.65 (+1.17%)

, NTRA

Natera

$106.24 /

+4.81 (+4.74%)

, NVTA

Invitae

$39.08 /

+ (+0.00%)

, RARE

Ultragenyx

$109.71 /

+1.59 (+1.47%)

, SNY

Sanofi

$50.68 /

+0.4199 (+0.84%)

, TAK

Takeda Pharmaceutical

$17.21 /

+0.155 (+0.91%)

, UA

Under Armour

$18.32 /

-0.115 (-0.62%)

, XFOR

X4 Pharmaceuticals

$8.77 /

-0.21 (-2.34%)

Annual Clinical Genetics…

Annual Clinical Genetics Virtual Meeting of ACMG to be held on April 13-16. Webcast Link

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$8.77 /

-0.21 (-2.34%)

UA Under Armour
$18.32 /

-0.115 (-0.62%)

TAK Takeda Pharmaceutical
$17.21 /

+0.155 (+0.91%)

SNY Sanofi
$50.68 /

+0.4199 (+0.84%)

RARE Ultragenyx
$109.71 /

+1.59 (+1.47%)

NVTA Invitae
$39.08 /

+ (+0.00%)

NTRA Natera
$106.24 /

+4.81 (+4.74%)

ILMN Illumina
$401.83 /

+4.65 (+1.17%)

FOLD Amicus
$10.33 /

+0.345 (+3.46%)

FIXX Homology Medicines
$7.03 /

-0.19 (-2.63%)

DGX Quest Diagnostics
$129.23 /

+2.03 (+1.60%)

CNTG Centogene
$11.67 /

-0.73 (-5.89%)

BNGO Bionano Genomics
$6.12 /

-0.305 (-4.75%)

APLT Applied Therapeutics
$16.73 /

+0.16 (+0.97%)

APLT Applied Therapeutics
$16.73 /

+0.16 (+0.97%)

11/17/20 Barclays
Applied Therapeutics price target lowered to $44 from $64 at Barclays
10/08/20 Truist
Applied Therapeutics initiated with a Buy at Truist
10/08/20 Truist
Applied Therapeutics initiated with a Buy at Truist
04/22/20
Fly Intel: Top five analyst initiations
BNGO Bionano Genomics
$6.12 /

-0.305 (-4.75%)

02/08/21 Oppenheimer
Bionano Genomics price target raised to $15 from $1.50 at Oppenheimer
01/26/21 Ladenburg
Bionano Genomics price target raised to $14 from $1.25 at Ladenburg
01/22/21 Maxim
Bionano Genomics price target raised to $14 from $2 at Maxim
12/04/20 Roth Capital
Bionano Genomics downgraded to Neutral from Buy at Roth Capital
CNTG Centogene
$11.67 /

-0.73 (-5.89%)

11/05/20 Credit Suisse
Centogene initiated with an Outperform at Credit Suisse
04/24/20 BTIG
Centogene price target raised to $23 from $18 at BTIG
04/24/20 Evercore ISI
Centogene downgraded to In Line from Outperform at Evercore ISI
DGX Quest Diagnostics
$129.23 /

+2.03 (+1.60%)

03/12/21 Baird
Quest Diagnostics downgraded to Neutral from Outperform at Baird
01/29/21 Citi
Quest Diagnostics price target raised to $158 from $151 at Citi
12/17/20 Morgan Stanley
Morgan Stanley cuts Quest Diagnostics to Equal Weight ahead of 2022 slowdown
12/17/20 Morgan Stanley
Quest Diagnostics downgraded to Equal Weight from Overweight at Morgan Stanley
FIXX Homology Medicines
$7.03 /

-0.19 (-2.63%)

03/01/21 Stifel
Homology Medicines initiated with a Hold at Stifel
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
FOLD Amicus
$10.33 /

+0.345 (+3.46%)

04/14/21 Cantor Fitzgerald
Amicus upgraded to Overweight from Neutral at Cantor Fitzgerald
04/13/21 Cantor Fitzgerald
Amicus upgraded to Overweight from Neutral at Cantor Fitzgerald
03/01/21 Stifel
Amicus initiated with a Hold at Stifel
02/12/21
Fly Intel: Top five analyst downgrades
ILMN Illumina
$401.83 /

+4.65 (+1.17%)

04/06/21 Wells Fargo
Illumina price target raised to $330 from $300 at Wells Fargo
04/06/21 Canaccord
Illumina price target raised to $460 from $445 at Canaccord
04/05/21 Evercore ISI
Evercore upgrades Edwards to Outperform ahead of its 'best pipeline cycle'
03/31/21 Canaccord
Canaccord upgrades Illumina, says worth owning with or without Grail
NTRA Natera
$106.24 /

+4.81 (+4.74%)

03/10/21 Piper Sandler
Natera, Genentech start Phase 3 trial using Signatera, says Piper Sandler
02/26/21 Piper Sandler
Natera price target raised to $150 from $127 at Piper Sandler
01/27/21 Truist
Natera initiated with a Buy at Truist
01/19/21 BTIG
Natera price target raised to $135 from $112 at BTIG
NVTA Invitae
$39.08 /

+ (+0.00%)

04/05/21 Oppenheimer
Oppenheimer upgrades Invitae on valuation, sees potential high $50s stock
04/05/21 Oppenheimer
Invitae upgraded to Outperform from Perform at Oppenheimer
02/18/21 Ladenburg
Invitae upgraded to Buy with $58 price target at Ladenburg
02/18/21 Ladenburg
Invitae upgraded to Buy from Neutral at Ladenburg
RARE Ultragenyx
$109.71 /

+1.59 (+1.47%)

03/24/21 Stifel
Stifel remains optimistic on GTX-102 and Ultragenyx ahead of 'important' update
03/01/21 Stifel
Ultragenyx resumed with a Buy at Stifel
02/12/21 Wedbush
Ultragenyx price target raised to $130 from $113 at Wedbush
02/12/21 Barclays
Ultragenyx price target raised to $186 from $176 at Barclays
SNY Sanofi
$50.68 /

+0.4199 (+0.84%)

04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
TAK Takeda Pharmaceutical
$17.21 /

+0.155 (+0.91%)

04/15/21 Oppenheimer
Molecular Templates price target lowered to $13 from $18 at Oppenheimer
04/05/21
Fly Intel: Top five analyst downgrades
04/05/21 Barclays
Molecular Templates MT-3724 discontinuation shouldn't be surprise, says Barclays
04/05/21 Jefferies
Takeda Pharmaceutical downgraded to Hold from Buy at Jefferies
UA Under Armour
$18.32 /

-0.115 (-0.62%)

02/22/21 Williams Capital
Under Armour initiated with a Hold at Williams Trading
02/19/21 Oppenheimer
Opco upgrades Under Armour on potential return to 'outsized' sales growth
02/19/21 Oppenheimer
Under Armour upgraded to Outperform from Perform at Oppenheimer
02/11/21 Jefferies
Under Armour price target raised to $30 from $25 at Jefferies
XFOR X4 Pharmaceuticals
$8.77 /

-0.21 (-2.34%)

12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
06/12/20 Roth Capital
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
XFOR X4 Pharmaceuticals
$8.77 /

-0.21 (-2.34%)

UA Under Armour
$18.32 /

-0.115 (-0.62%)

TAK Takeda Pharmaceutical
$17.21 /

+0.155 (+0.91%)

SNY Sanofi
$50.68 /

+0.4199 (+0.84%)

RARE Ultragenyx
$109.71 /

+1.59 (+1.47%)

NVTA Invitae
$39.08 /

+ (+0.00%)

NTRA Natera
$106.24 /

+4.81 (+4.74%)

ILMN Illumina
$401.83 /

+4.65 (+1.17%)

FOLD Amicus
$10.33 /

+0.345 (+3.46%)

FIXX Homology Medicines
$7.03 /

-0.19 (-2.63%)

DGX Quest Diagnostics
$129.23 /

+2.03 (+1.60%)

CNTG Centogene
$11.67 /

-0.73 (-5.89%)

BNGO Bionano Genomics
$6.12 /

-0.305 (-4.75%)

APLT Applied Therapeutics
$16.73 /

+0.16 (+0.97%)

  • 07
    Apr
  • 12
    Feb
  • 22
    Jan
  • 20
    Jan
  • 08
    Jan
  • 29
    Oct
  • 11
    Sep
  • 10
    Jul
UA Under Armour
$18.32 /

-0.115 (-0.62%)

SNY Sanofi
$50.68 /

+0.4199 (+0.84%)

ILMN Illumina
$401.83 /

+4.65 (+1.17%)

FOLD Amicus
$10.33 /

+0.345 (+3.46%)

UA Under Armour
$18.32 /

-0.115 (-0.62%)

TAK Takeda Pharmaceutical
$17.21 /

+0.155 (+0.91%)

SNY Sanofi
$50.68 /

+0.4199 (+0.84%)

NVTA Invitae
$39.08 /

+ (+0.00%)

NTRA Natera
$106.24 /

+4.81 (+4.74%)

ILMN Illumina
$401.83 /

+4.65 (+1.17%)

FOLD Amicus
$10.33 /

+0.345 (+3.46%)

FIXX Homology Medicines
$7.03 /

-0.19 (-2.63%)

DGX Quest Diagnostics
$129.23 /

+2.03 (+1.60%)

BNGO Bionano Genomics
$6.12 /

-0.305 (-4.75%)

APLT Applied Therapeutics
$16.73 /

+0.16 (+0.97%)

UA Under Armour
$18.32 /

-0.115 (-0.62%)

TAK Takeda Pharmaceutical
$17.21 /

+0.155 (+0.91%)

NVTA Invitae
$39.08 /

+ (+0.00%)

ILMN Illumina
$401.83 /

+4.65 (+1.17%)

FOLD Amicus
$10.33 /

+0.345 (+3.46%)

DGX Quest Diagnostics
$129.23 /

+2.03 (+1.60%)

BNGO Bionano Genomics
$6.12 /

-0.305 (-4.75%)

Earnings
Centogene reports Q4 revenue EUR70.3M, consensus $50.8M » 06:34
04/15/21
04/15
06:34
04/15/21
06:34
CNTG

Centogene

$12.23 /

-0.87 (-6.64%)

CEO Andrin Oswald said,…

CEO Andrin Oswald said, "We are pleased to see the significant revenue achieved with our commercial COVID-19 testing, and are positioned to invest the associated financial contributions into our core rare disease business. As such, we expect to see continued expansion in our key assets, such as our database and biobank, artificial intelligence, and research and development of rare genetic diseases. We anticipate a return to solid core business growth in 2021." CFO Richard Stoffelen added, "We are pleased with Centogene's performance in 2020, particularly in achieving record revenue growth and the highest annual adjusted EBITDA in the company's history amid a global pandemic. As we continue into 2021, we will use our significantly strengthened balance sheet and extensive knowledge of rare diseases to continue to deliver value to our patients and shareholders."

ShowHide Related Items >><<
CNTG Centogene
$12.23 /

-0.87 (-6.64%)

CNTG Centogene
$12.23 /

-0.87 (-6.64%)

11/05/20 Credit Suisse
Centogene initiated with an Outperform at Credit Suisse
04/24/20 BTIG
Centogene price target raised to $23 from $18 at BTIG
04/24/20 Evercore ISI
Centogene downgraded to In Line from Outperform at Evercore ISI
CNTG Centogene
$12.23 /

-0.87 (-6.64%)

  • 10
    Jul
Conference/Events
American College of Medical Genetics & Genomics » 04:55
04/15/21
04/15
04:55
04/15/21
04:55
APLT

Applied Therapeutics

$16.57 /

+0.04 (+0.24%)

, BNGO

Bionano Genomics

$6.42 /

-0.47 (-6.82%)

, CNTG

Centogene

$12.23 /

-0.87 (-6.64%)

, DGX

Quest Diagnostics

$127.31 /

-1.055 (-0.82%)

, FIXX

Homology Medicines

$7.22 /

+0.05 (+0.70%)

, FOLD

Amicus

$9.98 /

+0.67 (+7.20%)

, ILMN

Illumina

$398.29 /

-4.72 (-1.17%)

, NTRA

Natera

$101.43 /

-5.78 (-5.39%)

, NVTA

Invitae

$39.08 /

-0.29 (-0.74%)

, RARE

Ultragenyx

$107.91 /

+1.26 (+1.18%)

, SNY

Sanofi

$50.26 /

+0.16 (+0.32%)

, TAK

Takeda Pharmaceutical

$17.06 /

+0.055 (+0.32%)

, UA

Under Armour

$18.43 /

-0.13 (-0.70%)

, XFOR

X4 Pharmaceuticals

$8.98 /

+0.6 (+7.16%)

Annual Clinical Genetics…

Annual Clinical Genetics Virtual Meeting of ACMG to be held on April 13-16. Webcast Link

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$8.98 /

+0.6 (+7.16%)

UA Under Armour
$18.43 /

-0.13 (-0.70%)

TAK Takeda Pharmaceutical
$17.06 /

+0.055 (+0.32%)

SNY Sanofi
$50.26 /

+0.16 (+0.32%)

RARE Ultragenyx
$107.91 /

+1.26 (+1.18%)

NVTA Invitae
$39.08 /

-0.29 (-0.74%)

NTRA Natera
$101.43 /

-5.78 (-5.39%)

ILMN Illumina
$398.29 /

-4.72 (-1.17%)

FOLD Amicus
$9.98 /

+0.67 (+7.20%)

FIXX Homology Medicines
$7.22 /

+0.05 (+0.70%)

DGX Quest Diagnostics
$127.31 /

-1.055 (-0.82%)

CNTG Centogene
$12.23 /

-0.87 (-6.64%)

BNGO Bionano Genomics
$6.42 /

-0.47 (-6.82%)

APLT Applied Therapeutics
$16.57 /

+0.04 (+0.24%)

APLT Applied Therapeutics
$16.57 /

+0.04 (+0.24%)

11/17/20 Barclays
Applied Therapeutics price target lowered to $44 from $64 at Barclays
10/08/20 Truist
Applied Therapeutics initiated with a Buy at Truist
10/08/20 Truist
Applied Therapeutics initiated with a Buy at Truist
04/22/20
Fly Intel: Top five analyst initiations
BNGO Bionano Genomics
$6.42 /

-0.47 (-6.82%)

02/08/21 Oppenheimer
Bionano Genomics price target raised to $15 from $1.50 at Oppenheimer
01/26/21 Ladenburg
Bionano Genomics price target raised to $14 from $1.25 at Ladenburg
01/22/21 Maxim
Bionano Genomics price target raised to $14 from $2 at Maxim
12/04/20 Roth Capital
Bionano Genomics downgraded to Neutral from Buy at Roth Capital
CNTG Centogene
$12.23 /

-0.87 (-6.64%)

11/05/20 Credit Suisse
Centogene initiated with an Outperform at Credit Suisse
04/24/20 BTIG
Centogene price target raised to $23 from $18 at BTIG
04/24/20 Evercore ISI
Centogene downgraded to In Line from Outperform at Evercore ISI
DGX Quest Diagnostics
$127.31 /

-1.055 (-0.82%)

03/12/21 Baird
Quest Diagnostics downgraded to Neutral from Outperform at Baird
01/29/21 Citi
Quest Diagnostics price target raised to $158 from $151 at Citi
12/17/20 Morgan Stanley
Morgan Stanley cuts Quest Diagnostics to Equal Weight ahead of 2022 slowdown
12/17/20 Morgan Stanley
Quest Diagnostics downgraded to Equal Weight from Overweight at Morgan Stanley
FIXX Homology Medicines
$7.22 /

+0.05 (+0.70%)

03/01/21 Stifel
Homology Medicines initiated with a Hold at Stifel
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
FOLD Amicus
$9.98 /

+0.67 (+7.20%)

04/14/21 Cantor Fitzgerald
Amicus upgraded to Overweight from Neutral at Cantor Fitzgerald
04/13/21 Cantor Fitzgerald
Amicus upgraded to Overweight from Neutral at Cantor Fitzgerald
03/01/21 Stifel
Amicus initiated with a Hold at Stifel
02/12/21
Fly Intel: Top five analyst downgrades
ILMN Illumina
$398.29 /

-4.72 (-1.17%)

04/06/21 Wells Fargo
Illumina price target raised to $330 from $300 at Wells Fargo
04/06/21 Canaccord
Illumina price target raised to $460 from $445 at Canaccord
04/05/21 Evercore ISI
Evercore upgrades Edwards to Outperform ahead of its 'best pipeline cycle'
03/31/21 Canaccord
Canaccord upgrades Illumina, says worth owning with or without Grail
NTRA Natera
$101.43 /

-5.78 (-5.39%)

03/10/21 Piper Sandler
Natera, Genentech start Phase 3 trial using Signatera, says Piper Sandler
02/26/21 Piper Sandler
Natera price target raised to $150 from $127 at Piper Sandler
01/27/21 Truist
Natera initiated with a Buy at Truist
01/19/21 BTIG
Natera price target raised to $135 from $112 at BTIG
NVTA Invitae
$39.08 /

-0.29 (-0.74%)

04/05/21 Oppenheimer
Oppenheimer upgrades Invitae on valuation, sees potential high $50s stock
04/05/21 Oppenheimer
Invitae upgraded to Outperform from Perform at Oppenheimer
02/18/21 Ladenburg
Invitae upgraded to Buy with $58 price target at Ladenburg
02/18/21 Ladenburg
Invitae upgraded to Buy from Neutral at Ladenburg
RARE Ultragenyx
$107.91 /

+1.26 (+1.18%)

03/24/21 Stifel
Stifel remains optimistic on GTX-102 and Ultragenyx ahead of 'important' update
03/01/21 Stifel
Ultragenyx resumed with a Buy at Stifel
02/12/21 Wedbush
Ultragenyx price target raised to $130 from $113 at Wedbush
02/12/21 Barclays
Ultragenyx price target raised to $186 from $176 at Barclays
SNY Sanofi
$50.26 /

+0.16 (+0.32%)

04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
TAK Takeda Pharmaceutical
$17.06 /

+0.055 (+0.32%)

04/05/21
Fly Intel: Top five analyst downgrades
04/05/21 Barclays
Molecular Templates MT-3724 discontinuation shouldn't be surprise, says Barclays
04/05/21 Jefferies
Takeda Pharmaceutical downgraded to Hold from Buy at Jefferies
03/03/21 RBC Capital
Ovid downgraded to Sector Perform at RBC Capital after rally on Takeda deal
UA Under Armour
$18.43 /

-0.13 (-0.70%)

02/22/21 Williams Capital
Under Armour initiated with a Hold at Williams Trading
02/19/21 Oppenheimer
Opco upgrades Under Armour on potential return to 'outsized' sales growth
02/19/21 Oppenheimer
Under Armour upgraded to Outperform from Perform at Oppenheimer
02/11/21 Jefferies
Under Armour price target raised to $30 from $25 at Jefferies
XFOR X4 Pharmaceuticals
$8.98 /

+0.6 (+7.16%)

12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
06/12/20 Roth Capital
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
XFOR X4 Pharmaceuticals
$8.98 /

+0.6 (+7.16%)

UA Under Armour
$18.43 /

-0.13 (-0.70%)

TAK Takeda Pharmaceutical
$17.06 /

+0.055 (+0.32%)

SNY Sanofi
$50.26 /

+0.16 (+0.32%)

RARE Ultragenyx
$107.91 /

+1.26 (+1.18%)

NVTA Invitae
$39.08 /

-0.29 (-0.74%)

NTRA Natera
$101.43 /

-5.78 (-5.39%)

ILMN Illumina
$398.29 /

-4.72 (-1.17%)

FOLD Amicus
$9.98 /

+0.67 (+7.20%)

FIXX Homology Medicines
$7.22 /

+0.05 (+0.70%)

DGX Quest Diagnostics
$127.31 /

-1.055 (-0.82%)

CNTG Centogene
$12.23 /

-0.87 (-6.64%)

BNGO Bionano Genomics
$6.42 /

-0.47 (-6.82%)

APLT Applied Therapeutics
$16.57 /

+0.04 (+0.24%)

  • 07
    Apr
  • 12
    Feb
  • 22
    Jan
  • 20
    Jan
  • 08
    Jan
  • 29
    Oct
  • 11
    Sep
  • 10
    Jul
UA Under Armour
$18.43 /

-0.13 (-0.70%)

SNY Sanofi
$50.26 /

+0.16 (+0.32%)

ILMN Illumina
$398.29 /

-4.72 (-1.17%)

FOLD Amicus
$9.98 /

+0.67 (+7.20%)

UA Under Armour
$18.43 /

-0.13 (-0.70%)

TAK Takeda Pharmaceutical
$17.06 /

+0.055 (+0.32%)

SNY Sanofi
$50.26 /

+0.16 (+0.32%)

NVTA Invitae
$39.08 /

-0.29 (-0.74%)

NTRA Natera
$101.43 /

-5.78 (-5.39%)

ILMN Illumina
$398.29 /

-4.72 (-1.17%)

FOLD Amicus
$9.98 /

+0.67 (+7.20%)

FIXX Homology Medicines
$7.22 /

+0.05 (+0.70%)

DGX Quest Diagnostics
$127.31 /

-1.055 (-0.82%)

BNGO Bionano Genomics
$6.42 /

-0.47 (-6.82%)

APLT Applied Therapeutics
$16.57 /

+0.04 (+0.24%)

UA Under Armour
$18.43 /

-0.13 (-0.70%)

TAK Takeda Pharmaceutical
$17.06 /

+0.055 (+0.32%)

NVTA Invitae
$39.08 /

-0.29 (-0.74%)

ILMN Illumina
$398.29 /

-4.72 (-1.17%)

FOLD Amicus
$9.98 /

+0.67 (+7.20%)

DGX Quest Diagnostics
$127.31 /

-1.055 (-0.82%)

BNGO Bionano Genomics
$6.42 /

-0.47 (-6.82%)

Conference/Events
American College of Medical Genetics & Genomics » 08:54
04/14/21
04/14
08:54
04/14/21
08:54
APLT

Applied Therapeutics

$16.50 /

+0.17 (+1.04%)

, BNGO

Bionano Genomics

$6.89 /

+0.145 (+2.15%)

, CNTG

Centogene

$13.15 /

+0.725 (+5.84%)

, DGX

Quest Diagnostics

$128.37 /

-0.485 (-0.38%)

, FIXX

Homology Medicines

$7.17 /

+0.01 (+0.14%)

, FOLD

Amicus

$9.30 /

+0.01 (+0.11%)

, ILMN

Illumina

$403.03 /

+4.28 (+1.07%)

, NTRA

Natera

$107.16 /

+3.3 (+3.18%)

, NVTA

Invitae

$39.37 /

+1.81 (+4.82%)

, RARE

Ultragenyx

$106.48 /

+5.97 (+5.94%)

, SNY

Sanofi

$50.10 /

-0.17 (-0.34%)

, TAK

Takeda Pharmaceutical

$17.00 /

-0.145 (-0.85%)

, UA

Under Armour

$18.56 /

-0.625 (-3.26%)

, XFOR

X4 Pharmaceuticals

$8.44 /

-0.16 (-1.86%)

Annual Clinical Genetics…

Annual Clinical Genetics Virtual Meeting of ACMG to be held on April 13-16. Webcast Link

ShowHide Related Items >><<
XFOR X4 Pharmaceuticals
$8.44 /

-0.16 (-1.86%)

UA Under Armour
$18.56 /

-0.625 (-3.26%)

TAK Takeda Pharmaceutical
$17.00 /

-0.145 (-0.85%)

SNY Sanofi
$50.10 /

-0.17 (-0.34%)

RARE Ultragenyx
$106.48 /

+5.97 (+5.94%)

NVTA Invitae
$39.37 /

+1.81 (+4.82%)

NTRA Natera
$107.16 /

+3.3 (+3.18%)

ILMN Illumina
$403.03 /

+4.28 (+1.07%)

FOLD Amicus
$9.30 /

+0.01 (+0.11%)

FIXX Homology Medicines
$7.17 /

+0.01 (+0.14%)

DGX Quest Diagnostics
$128.37 /

-0.485 (-0.38%)

CNTG Centogene
$13.15 /

+0.725 (+5.84%)

BNGO Bionano Genomics
$6.89 /

+0.145 (+2.15%)

APLT Applied Therapeutics
$16.50 /

+0.17 (+1.04%)

APLT Applied Therapeutics
$16.50 /

+0.17 (+1.04%)

11/17/20 Barclays
Applied Therapeutics price target lowered to $44 from $64 at Barclays
10/08/20 Truist
Applied Therapeutics initiated with a Buy at Truist
10/08/20 Truist
Applied Therapeutics initiated with a Buy at Truist
04/22/20
Fly Intel: Top five analyst initiations
BNGO Bionano Genomics
$6.89 /

+0.145 (+2.15%)

02/08/21 Oppenheimer
Bionano Genomics price target raised to $15 from $1.50 at Oppenheimer
01/26/21 Ladenburg
Bionano Genomics price target raised to $14 from $1.25 at Ladenburg
01/22/21 Maxim
Bionano Genomics price target raised to $14 from $2 at Maxim
12/04/20 Roth Capital
Bionano Genomics downgraded to Neutral from Buy at Roth Capital
CNTG Centogene
$13.15 /

+0.725 (+5.84%)

11/05/20 Credit Suisse
Centogene initiated with an Outperform at Credit Suisse
04/24/20 BTIG
Centogene price target raised to $23 from $18 at BTIG
04/24/20 Evercore ISI
Centogene downgraded to In Line from Outperform at Evercore ISI
DGX Quest Diagnostics
$128.37 /

-0.485 (-0.38%)

03/12/21 Baird
Quest Diagnostics downgraded to Neutral from Outperform at Baird
01/29/21 Citi
Quest Diagnostics price target raised to $158 from $151 at Citi
12/17/20 Morgan Stanley
Morgan Stanley cuts Quest Diagnostics to Equal Weight ahead of 2022 slowdown
12/17/20 Morgan Stanley
Quest Diagnostics downgraded to Equal Weight from Overweight at Morgan Stanley
FIXX Homology Medicines
$7.17 /

+0.01 (+0.14%)

03/01/21 Stifel
Homology Medicines initiated with a Hold at Stifel
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
FOLD Amicus
$9.30 /

+0.01 (+0.11%)

04/14/21 Cantor Fitzgerald
Amicus upgraded to Overweight from Neutral at Cantor Fitzgerald
04/13/21 Cantor Fitzgerald
Amicus upgraded to Overweight from Neutral at Cantor Fitzgerald
03/01/21 Stifel
Amicus initiated with a Hold at Stifel
02/12/21
Fly Intel: Top five analyst downgrades
ILMN Illumina
$403.03 /

+4.28 (+1.07%)

04/06/21 Wells Fargo
Illumina price target raised to $330 from $300 at Wells Fargo
04/06/21 Canaccord
Illumina price target raised to $460 from $445 at Canaccord
04/05/21 Evercore ISI
Evercore upgrades Edwards to Outperform ahead of its 'best pipeline cycle'
03/31/21 Canaccord
Canaccord upgrades Illumina, says worth owning with or without Grail
NTRA Natera
$107.16 /

+3.3 (+3.18%)

03/10/21 Piper Sandler
Natera, Genentech start Phase 3 trial using Signatera, says Piper Sandler
02/26/21 Piper Sandler
Natera price target raised to $150 from $127 at Piper Sandler
01/27/21 Truist
Natera initiated with a Buy at Truist
01/19/21 BTIG
Natera price target raised to $135 from $112 at BTIG
NVTA Invitae
$39.37 /

+1.81 (+4.82%)

04/05/21 Oppenheimer
Oppenheimer upgrades Invitae on valuation, sees potential high $50s stock
04/05/21 Oppenheimer
Invitae upgraded to Outperform from Perform at Oppenheimer
02/18/21 Ladenburg
Invitae upgraded to Buy with $58 price target at Ladenburg
02/18/21 Ladenburg
Invitae upgraded to Buy from Neutral at Ladenburg
RARE Ultragenyx
$106.48 /

+5.97 (+5.94%)

03/24/21 Stifel
Stifel remains optimistic on GTX-102 and Ultragenyx ahead of 'important' update
03/01/21 Stifel
Ultragenyx resumed with a Buy at Stifel
02/12/21 Wedbush
Ultragenyx price target raised to $130 from $113 at Wedbush
02/12/21 Barclays
Ultragenyx price target raised to $186 from $176 at Barclays
SNY Sanofi
$50.10 /

-0.17 (-0.34%)

04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
TAK Takeda Pharmaceutical
$17.00 /

-0.145 (-0.85%)

04/05/21
Fly Intel: Top five analyst downgrades
04/05/21 Barclays
Molecular Templates MT-3724 discontinuation shouldn't be surprise, says Barclays
04/05/21 Jefferies
Takeda Pharmaceutical downgraded to Hold from Buy at Jefferies
03/03/21 RBC Capital
Ovid downgraded to Sector Perform at RBC Capital after rally on Takeda deal
UA Under Armour
$18.56 /

-0.625 (-3.26%)

02/22/21 Williams Capital
Under Armour initiated with a Hold at Williams Trading
02/19/21 Oppenheimer
Opco upgrades Under Armour on potential return to 'outsized' sales growth
02/19/21 Oppenheimer
Under Armour upgraded to Outperform from Perform at Oppenheimer
02/11/21 Jefferies
Under Armour price target raised to $30 from $25 at Jefferies
XFOR X4 Pharmaceuticals
$8.44 /

-0.16 (-1.86%)

12/17/20 Brookline
X4 Pharmaceuticals initiated with a Buy at Brookline
12/14/20 Roth Capital
New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
06/12/20 Roth Capital
X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
XFOR X4 Pharmaceuticals
$8.44 /

-0.16 (-1.86%)

UA Under Armour
$18.56 /

-0.625 (-3.26%)

TAK Takeda Pharmaceutical
$17.00 /

-0.145 (-0.85%)

SNY Sanofi
$50.10 /

-0.17 (-0.34%)

RARE Ultragenyx
$106.48 /

+5.97 (+5.94%)

NVTA Invitae
$39.37 /

+1.81 (+4.82%)

NTRA Natera
$107.16 /

+3.3 (+3.18%)

ILMN Illumina
$403.03 /

+4.28 (+1.07%)

FOLD Amicus
$9.30 /

+0.01 (+0.11%)

FIXX Homology Medicines
$7.17 /

+0.01 (+0.14%)

DGX Quest Diagnostics
$128.37 /

-0.485 (-0.38%)

CNTG Centogene
$13.15 /

+0.725 (+5.84%)

BNGO Bionano Genomics
$6.89 /

+0.145 (+2.15%)

APLT Applied Therapeutics
$16.50 /

+0.17 (+1.04%)

  • 07
    Apr
  • 12
    Feb
  • 22
    Jan
  • 20
    Jan
  • 08
    Jan
  • 29
    Oct
  • 11
    Sep
  • 10
    Jul
UA Under Armour
$18.56 /

-0.625 (-3.26%)

SNY Sanofi
$50.10 /

-0.17 (-0.34%)

ILMN Illumina
$403.03 /

+4.28 (+1.07%)

FOLD Amicus
$9.30 /

+0.01 (+0.11%)

UA Under Armour
$18.56 /

-0.625 (-3.26%)

TAK Takeda Pharmaceutical
$17.00 /

-0.145 (-0.85%)

SNY Sanofi
$50.10 /

-0.17 (-0.34%)

NVTA Invitae
$39.37 /

+1.81 (+4.82%)

NTRA Natera
$107.16 /

+3.3 (+3.18%)

ILMN Illumina
$403.03 /

+4.28 (+1.07%)

FOLD Amicus
$9.30 /

+0.01 (+0.11%)

FIXX Homology Medicines
$7.17 /

+0.01 (+0.14%)

DGX Quest Diagnostics
$128.37 /

-0.485 (-0.38%)

BNGO Bionano Genomics
$6.89 /

+0.145 (+2.15%)

APLT Applied Therapeutics
$16.50 /

+0.17 (+1.04%)

UA Under Armour
$18.56 /

-0.625 (-3.26%)

TAK Takeda Pharmaceutical
$17.00 /

-0.145 (-0.85%)

NVTA Invitae
$39.37 /

+1.81 (+4.82%)

ILMN Illumina
$403.03 /

+4.28 (+1.07%)

FOLD Amicus
$9.30 /

+0.01 (+0.11%)

DGX Quest Diagnostics
$128.37 /

-0.485 (-0.38%)

BNGO Bionano Genomics
$6.89 /

+0.145 (+2.15%)

Hot Stocks
Centogene extends partnership with Takeda Pharmaceutical » 06:33
04/14/21
04/14
06:33
04/14/21
06:33
CNTG

Centogene

$13.15 /

+0.725 (+5.84%)

, TAK

Takeda Pharmaceutical

$17.00 /

-0.145 (-0.85%)

Centogene announced that…

Centogene announced that it has extended its partnership with Takeda Pharmaceutical (TAK) to diagnose patients with certain genetic disorders. As part of the agreement, which has been extended until March 2022, Centogene will continue providing access to genetic testing to patients around the world. In January 2015, Centogene originally entered into an agreement with Shire Pharmaceuticals, which is now a subsidiary of Takeda, to provide diagnostic testing capability to enhance early diagnosis of patients suffering from genetic rare diseases.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$17.00 /

-0.145 (-0.85%)

CNTG Centogene
$13.15 /

+0.725 (+5.84%)

CNTG Centogene
$13.15 /

+0.725 (+5.84%)

11/05/20 Credit Suisse
Centogene initiated with an Outperform at Credit Suisse
04/24/20 BTIG
Centogene price target raised to $23 from $18 at BTIG
04/24/20 Evercore ISI
Centogene downgraded to In Line from Outperform at Evercore ISI
TAK Takeda Pharmaceutical
$17.00 /

-0.145 (-0.85%)

04/05/21
Fly Intel: Top five analyst downgrades
04/05/21 Barclays
Molecular Templates MT-3724 discontinuation shouldn't be surprise, says Barclays
04/05/21 Jefferies
Takeda Pharmaceutical downgraded to Hold from Buy at Jefferies
03/03/21 RBC Capital
Ovid downgraded to Sector Perform at RBC Capital after rally on Takeda deal
TAK Takeda Pharmaceutical
$17.00 /

-0.145 (-0.85%)

CNTG Centogene
$13.15 /

+0.725 (+5.84%)

  • 10
    Jul
TAK Takeda Pharmaceutical
$17.00 /

-0.145 (-0.85%)

TAK Takeda Pharmaceutical
$17.00 /

-0.145 (-0.85%)

Over a quarter ago
Earnings
Centogene sees FY20 revenue over EUR100M  06:40
12/16/20
12/16
06:40
12/16/20
06:40
CNTG

Centogene

$11.59 /

-0.16 (-1.36%)

 
ShowHide Related Items >><<
CNTG Centogene
$11.59 /

-0.16 (-1.36%)

CNTG Centogene
$11.59 /

-0.16 (-1.36%)

11/05/20 Credit Suisse
Centogene initiated with an Outperform at Credit Suisse
04/24/20 BTIG
Centogene price target raised to $23 from $18 at BTIG
04/24/20 Evercore ISI
Centogene downgraded to In Line from Outperform at Evercore ISI
CNTG Centogene
$11.59 /

-0.16 (-1.36%)

  • 10
    Jul
CNTG Centogene
$11.59 /

-0.16 (-1.36%)

CNTG Centogene
$11.59 /

-0.16 (-1.36%)

Earnings
Centogene reports Q3 revenue EUR36.3M vs. EUR11.6M a year ago. » 06:39
12/16/20
12/16
06:39
12/16/20
06:39
CNTG

Centogene

$11.59 /

-0.16 (-1.36%)

CEO Andrin Oswald said,…

CEO Andrin Oswald said, "I am excited to have joined Centogene at such an important stage in the company's evolution. (...) I am looking forward to helping further scale and accelerate CENTOGENE's growth as a leader in the rare disease space". CFO Richard Stoffelen said, "During Q3, we saw a significant increase in our revenues, year-over-year, driven by our ability to leverage our core competency in precise medical diagnoses to pivot quickly and provide solutions to help address the COVID-19 pandemic. As we approach the end of what has been an unprecedented year, I would like to thank the entire Centogene team once more for their flexibility and unwavering commitment."

ShowHide Related Items >><<
CNTG Centogene
$11.59 /

-0.16 (-1.36%)

CNTG Centogene
$11.59 /

-0.16 (-1.36%)

11/05/20 Credit Suisse
Centogene initiated with an Outperform at Credit Suisse
04/24/20 BTIG
Centogene price target raised to $23 from $18 at BTIG
04/24/20 Evercore ISI
Centogene downgraded to In Line from Outperform at Evercore ISI
CNTG Centogene
$11.59 /

-0.16 (-1.36%)

  • 10
    Jul
CNTG Centogene
$11.59 /

-0.16 (-1.36%)

CNTG Centogene
$11.59 /

-0.16 (-1.36%)

Hot Stocks
Centogene, Alnylam launch joint clinical screening program » 06:34
12/08/20
12/08
06:34
12/08/20
06:34
CNTG

Centogene

$11.44 /

-0.2 (-1.72%)

, ALNY

Alnylam

$126.99 /

-2.48 (-1.92%)

Centogene (CNTG) and…

Centogene (CNTG) and Alnylam Pharmaceuticals (ALNY) announced the launch of a new joint clinical screening program: the genetic screening of the at-risk population for hereditary TransthyRetin-related AMyloidosis and longitudinal monitoring of TTR positive subjects. The new TRAMmoniTTR Study is a follow-up to the preceding epidemiological analysis for hereditary TransthyRetin-related AMyloidosis. Since 2017, 5,000 participants from Germany, Austria and Switzerland with polyneuropathy and/or cardiomyopathy of no obvious etiology have been screened for ATTRv as part of the TRAM Study. More than 1% of participants were eventually diagnosed with ATTRv, clinically characterized and regionally mapped. The follow-up TRAMmoniTTR Study will include both symptomatic and asymptomatic TTR positive participants, who will be invited to take part in the longitudinal phase to monitor their clinical status. Using CENTOGENE's metabolomics profiling platform, the company has discovered and now characterizes novel ATTRv biomarkers. Such molecules are crucial to accelerate ATTRv diagnostics and treatment personalization. The monitoring of these biomarkers in TTR positive participants will support the validation process.

ShowHide Related Items >><<
CNTG Centogene
$11.44 /

-0.2 (-1.72%)

ALNY Alnylam
$126.99 /

-2.48 (-1.92%)

CNTG Centogene
$11.44 /

-0.2 (-1.72%)

11/05/20 Credit Suisse
Centogene initiated with an Outperform at Credit Suisse
04/24/20 BTIG
Centogene price target raised to $23 from $18 at BTIG
04/24/20 Evercore ISI
Centogene downgraded to In Line from Outperform at Evercore ISI
ALNY Alnylam
$126.99 /

-2.48 (-1.92%)

11/24/20 BMO Capital
Alnylam price target raised to $183 at BMO Capital on early Oxlumo approval
11/24/20 Piper Sandler
Piper reiterates Overweight rating on Alnylam after Oxlumo approved
09/30/20 Berenberg
Alnylam reinitiated with a Hold at Berenberg
09/08/20 Citi
Alnylam initiated with a Buy at Citi
CNTG Centogene
$11.44 /

-0.2 (-1.72%)

ALNY Alnylam
$126.99 /

-2.48 (-1.92%)

  • 10
    Jul
CNTG Centogene
$11.44 /

-0.2 (-1.72%)

ALNY Alnylam
$126.99 /

-2.48 (-1.92%)

CNTG Centogene
$11.44 /

-0.2 (-1.72%)

ALNY Alnylam
$126.99 /

-2.48 (-1.92%)

Hot Stocks
Centogene expands partnership with PTC Therapeutics » 06:32
11/25/20
11/25
06:32
11/25/20
06:32
CNTG

Centogene

$11.40 /

+0.05 (+0.44%)

, PTCT

PTC Therapeutics

$63.24 /

+0.94 (+1.51%)

Centogene (CNTG)…

Centogene (CNTG) announced that it has expanded its partnership with PTC Therapeutics (PTCT). The companies will work together in several new regions including many countries in Europe, the Middle East, and Latin America to provide genetic testing and 3-O-Methyldopa biomarker analytics to help identify patients with Aromatic L-amino Acid Decarboxylase deficiency. AADC deficiency is a life-shortening, ultra-rare genetic disorder that causes severe disability and ongoing physical and mental suffering from the first few months of life. In addition, Centogene will now provide this testing and biomarker analytics for patients involved in the REVEAL CP study, a screening study designed to determine the prevalence of AADC deficiency in patients with cerebral palsy of unknown cause.

ShowHide Related Items >><<
PTCT PTC Therapeutics
$63.24 /

+0.94 (+1.51%)

CNTG Centogene
$11.40 /

+0.05 (+0.44%)

CNTG Centogene
$11.40 /

+0.05 (+0.44%)

11/05/20 Credit Suisse
Centogene initiated with an Outperform at Credit Suisse
04/24/20 BTIG
Centogene price target raised to $23 from $18 at BTIG
04/24/20 Evercore ISI
Centogene downgraded to In Line from Outperform at Evercore ISI
12/03/19 Baird
Centogene initiated with an Outperform at Baird
PTCT PTC Therapeutics
$63.24 /

+0.94 (+1.51%)

10/30/20 Citi
Citi downgrades PTC Therapeutics to Neutral, sees shares being range-bound
10/30/20 Citi
PTC Therapeutics downgraded to Neutral from Buy at Citi
10/30/20 Cantor Fitzgerald
PTC Therapeutics price target lowered to $67 from $75 at Cantor Fitzgerald
10/28/20 UBS
PTC Therapeutics initiated with a Neutral at UBS
PTCT PTC Therapeutics
$63.24 /

+0.94 (+1.51%)

CNTG Centogene
$11.40 /

+0.05 (+0.44%)

  • 10
    Jul
CNTG Centogene
$11.40 /

+0.05 (+0.44%)

PTCT PTC Therapeutics
$63.24 /

+0.94 (+1.51%)

CNTG Centogene
$11.40 /

+0.05 (+0.44%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.